PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

IntroductionEndeavors in the molecular characterization of breast cancer opened the doors to endocrine therapies in ER+/HER2- breast cancer, increasing response rates substantially. Despite that, taxane-based neoadjuvant chemotherapy is still a cornerstone for achieving breast-conserving surgery and...

Full description

Bibliographic Details
Main Author:	Gulnihal Ozcan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Oncology
Subjects:	breast cancer chemoresistance taxane-based neoadjuvant chemotherapy predictive markers precision medicine bioinformatics
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1216438/full

Similar Items

SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer
by: Gülnihal Özcan
Published: (2023-01-01)

Outcomes of Triple-Negative Breast Cancer Patients in Response to Taxane and Nontaxane-Based Neoadjuvant Chemotherapies
by: Mohsin Khan, et al.
Published: (2022-06-01)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
by: Shirin Kianersi, et al.
Published: (2023-01-01)

Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
by: Cheng Wang, et al.
Published: (2024-06-01)

The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting
by: Gulnihal Ozcan, et al.
Published: (2023-02-01)

TRP Channels: The Neglected Culprits in Breast Cancer Chemotherapy Resistance?
by: Mayar Soussi, et al.
Published: (2023-09-01)

Prognostic factors in patients with locally advanced breast cancer treated with neoadjuvant taxane-anthracycline combination chemotherapy
by: Chang-Eun Jang, et al.
Published: (2015-12-01)

Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
by: Houpu Yang, et al.
Published: (2022-12-01)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
by: Kai Conrad Cecil Johnson, et al.
Published: (2023-06-01)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
by: Yan Gao, et al.
Published: (2019-09-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01)

Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment
by: V. O. Bashlyk, et al.
Published: (2018-07-01)

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
by: Carlos A. Barrón-Gallardo, et al.
Published: (2022-10-01)

Editorial: Drug resistance in lung cancer chemotherapy and personalized chemotherapy
by: Lianbo Li
Published: (2022-08-01)

Assessment of Predictive Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer
by: Mallika Tewari, et al.
Published: (2010-10-01)

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
by: Freshte Foroughi, et al.
Published: (2024-12-01)

Cancer-associated fibroblasts: protagonists of the tumor microenvironment in gastric cancer
by: Ece Ozmen, et al.
Published: (2024-03-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: K Alimoghadam, et al.
Published: (2004-03-01)

Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study
by: Zhi Yang, et al.
Published: (2025-01-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

The frequency of chemotherapy induced amenorrhea in premenopausal patients with breast cancer in the Ayatollah Rohani hospital of Babol
by: Mohammad Ranaei, et al.
Published: (2021-05-01)

Cell death in cancer chemotherapy using taxanes
by: Ana P. Xu, et al.
Published: (2024-01-01)

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01)

Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report
by: Chieko Miyazaki, et al.
Published: (2019-09-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01)

Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer
by: Azra Rašić, et al.
Published: (2019-02-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
by: Taha Heba F., et al.
Published: (2021-05-01)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
by: Jonas Leichsenring, et al.
Published: (2022-10-01)

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
by: Lingfeng Tang, et al.
Published: (2024-05-01)

Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
by: Frank vanHaren, et al.
Published: (2022-10-01)

Neoadjuvant Chemotherapy in Nasopharyngeal Carcinoma
by: Khudair J. Sabeeh Al-Rawaq
Published: (2012-04-01)

View of Perceived Symptoms Associated with Chemotherapy-induced Peripheral Neuropathy in Patients with Breast Cancer: A Cross-sectional Study
by: Alper TUĞRAL, et al.
Published: (2024-08-01)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
by: Andreas Venizelos, et al.
Published: (2022-08-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
by: Knut Jørgen Labori, et al.
Published: (2022-04-01)

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016-09-01)

Recent advance in neoadjuvant chemotherapy for rectal cancer
by: GUO Yang, GUO Tian′an, XU Ye
Published: (2022-07-01)